Triple Negative Breast Cancer

被引：36
|
作者：
Cetin, Idil [1 ]
Topcul, Mehmet [2 ]
机构：
[1] Istanbul Univ, Fac Sci, Dept Radiobiol, Istanbul, Turkey
[2] Istanbul Univ, Fac Sci, Dept Biol, Istanbul, Turkey
来源：
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 2014年 / 15卷 / 06期
关键词：
Triple negative breast cancer; poor prognosis; targeted therapy; ENDOTHELIAL GROWTH-FACTOR; FACTOR RECEPTOR; MOLECULAR SUBTYPES; RISK-FACTORS; STEM-CELLS; PROGNOSTIC VALUE; BASAL; CHEMOTHERAPY; CARCINOMA; SURVIVAL;
D O I：
10.7314/APJCP.2014.15.6.2427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Triple-negative breast cancers (TNBC), characterized by absence of the estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), have a poor prognosis. To overcome therapy limitations of TNBC, various new approaches are needed. This mini-review focuses on discovery of new targets and drugs which might offer new hope for TNBC patients.
引用
收藏
页码：2427 / 2431
页数：5
相关论文
共 50 条
  • [31] Triple-negative breast cancer: current state of the art
    Rastelli, Francesca
    Biancanelli, Sandra
    Falzetta, Amalia
    Martignetti, Angelo
    Casi, Camilla
    Bascioni, Romeo
    Giustini, Lucio
    Crispino, Sergio
    TUMORI JOURNAL, 2010, 96 (06): : 875 - 888
  • [32] Hyperoxygenation as a Therapeutic Supplement for Treatment of Triple Negative Breast Cancer
    Mast, Jesse M.
    Kuppusamy, Periannan
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [33] Subtyping of Triple-Negative Breast Cancer: Implications for Therapy
    Abramson, Vandana G.
    Lehmann, Brian D.
    Ballinger, Tarah J.
    Pietenpol, Jennifer A.
    CANCER, 2015, 121 (01) : 8 - 16
  • [34] Advances in the systemic treatment of triple-negative breast cancer
    Lebert, J. M.
    Lester, R.
    Powell, E.
    Seal, M.
    McCarthy, J.
    CURRENT ONCOLOGY, 2018, 25 : S142 - S150
  • [35] The clinical promise of immunotherapy in triple-negative breast cancer
    Vikas, Praveen
    Borcherding, Nicholas
    Zhang, Weizhou
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 6823 - 6833
  • [36] Role of transforming growth factor-β1 in triple negative breast cancer patients
    Zhang, Mingxia
    Wu, Jiannan
    Mao, Kai
    Deng, Heran
    Yang, Yaping
    Zhou, Enxiang
    Liu, Jieqiong
    INTERNATIONAL JOURNAL OF SURGERY, 2017, 45 : 72 - 76
  • [37] Directed Therapy of Subtypes of Triple-Negative Breast Cancer
    Carey, Lisa A.
    ONCOLOGIST, 2011, 16 : 71 - 78
  • [38] Update on systemic treatment in early triple negative breast cancer
    Nunez Abad, Martin
    Calabuig-Farinas, Silvia
    Lobo de Mena, Miriam
    Sanz de Bremond, Maria Jose Godes
    Garcia Gonzalez, Clara
    Torres Martinez, Susana
    Angel Garcia-Garcia, Jose
    Iranzo Gonzalez-Cruz, Vega
    Camps Herrero, Carlos
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [39] Overview of recent advances in metastatic triple negative breast cancer
    O'Reilly, David
    Al Sendi, Maha
    Kelly, Catherine M.
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (03): : 164 - 182
  • [40] ERCC1 expression in triple negative breast cancer
    Ozkan, C.
    Gumuskaya, B.
    Yaman, S.
    Aksoy, S.
    Guler, G.
    Altundag, K.
    JOURNAL OF BUON, 2012, 17 (02): : 271 - 276
12345